Pfizer cited many reasons for ending sales of hemophilia B gene therapy Beqvez, including a lack of patient and doctor interest. The company no longer plans to develop AAV gene therapies.
Beqvez was the last gene therapy left in Pfizer's portfolio (Shutterstock)
Key Takeaways
Pfizer will end global development and commercialization of hemophilia B gene therapy Beqvez due to a lack of patient and doctor interest, terminating the last of its AAV gene therapy programs.
Less than two months after Pfizer opted to give up its rights to late-stage Sangamo Therapeutics-partnered hemophilia A gene therapy...
